Share on LinkedInShare on LinkedIn

ARTICLE · 17 AUGUST 2016

Franklin Templeton, K2 Launch Global Macro Liquid Alt Fund

Herbert Smith Freehills Kramer LLP
Herbert Smith Freehills Kramer LLP
Contributor
Herbert Smith Freehills Kramer LLP

Herbert Smith Freehills Kramer LLP

We have one of the largest Southeast Asia international law practices, working across the region...

View firm profile
Explore more from Herbert Smith Freehills Kramer LLP

Franklin Templeton, along with its alternatives unit K2 Advisors, launched the Franklin K2 Global Macro Opportunities Fund.

United StatesFinance and Banking
Ann Kalodis
Ann Kalodis
Author LinkedIn connections

Franklin Templeton, along with its alternatives unit K2 Advisors, launched the Franklin K2 Global Macro Opportunities Fund. The liquid alternative mutual fund will use a multi-manager macro strategy to invest in a range of global macro opportunities across equity, interest rate, currency and commodity markets and strategies. K2's Rob Christian and Anthony Zanolla will manage the fund, which is sub-advised by several hedge funds, including Aspect Capital Limited, Emso Asset Management Limited and Graham Capital Management.
Link To Article

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

View source

Related Articles

Legal Intelligence Newsletters

Read more about

Related Comparative Guides

See more popular content from

Article

SEC And CFTC Open Door To Tokenized Markets After Clarity Fails To Advance

The SEC and CFTC have issued coordinated regulatory relief measures that significantly advance crypto-based trading infrastructure in US markets, bypassing Congressional gridlock on the CLARITY Act. These orders establish new frameworks for tokenized securities venues and passive software providers, potentially reshaping how digital assets are traded and accessed in regulated markets.
United StatesFinance and Banking
K&L Gates
K&L Gates
Article

The Desk: July Edition

The CFTC continues its regulatory evolution with significant developments in June 2026, including the rescission of its longstanding no-deny settlement policy, proposed amendments to whistleblower protections, and joint harmonization efforts with the SEC on data reporting and portfolio margining. The agency also advances its oversight of prediction markets while CME Group challenges the CFTC's characterization of cryptocurrency perpetual futures contracts.
United StatesFinance and Banking
Moore & Van Allen, PLLC
Moore & Van Allen, PLLC
Article

HRSA Announces Updated 340B Rebate Model Pilot Program, Limited To Drugs Subject To A Maximum Fair Price (MFP) For 2026 And 2027

The Health Resources and Services Administration has announced a revised 340B Rebate Model Pilot Program for drugs subject to Medicare's Maximum Fair Price, expanding eligibility to manufacturers with selected drugs for 2026 and 2027. The program introduces new data requirements, dispute resolution mechanisms, and stricter compliance monitoring while addressing stakeholder concerns about administrative burden and program integrity.
United StatesFinance and Banking
Hogan Lovells Cadwalader
Hogan Lovells Cadwalader
Article

The SEC’s Proposed “Regulation Crypto Assets” Provides A New Framework For Regulatory Clarity

The U.S. Securities and Exchange Commission has proposed Regulation Crypto Assets, introducing two new exemptions from registration requirements and a safe harbor provision for investment contracts involving crypto assets. How will these tailored frameworks—the Startup Exemption for offerings up to $5M and the Fundraising Exemption for larger capital raises—reshape the regulatory landscape for digital asset issuers while preserving investor protections?
United StatesFinance and Banking
Winston Taylor
Winston Taylor
Article

2026 Sees China's Biotech Scene Continuing Its Ascent – But Could US Developments Mean Clouds On The Horizon?

In recent years, China's biotech scene has risen in prominence with its innovative R&D and promising pipelines commanding big pharma's attention. In this blog, we take a look at this trend, which sees China-related deals and investment continuing to flow, as well as the recent developments in the US, with draft legislation being proposed that seeks to impose restrictions which would impact transactions between US pharma companies and Chinese biotechs. 
GlobalFood, Drugs, Healthcare, Life Sciences
Herbert Smith Freehills Kramer LLP
Herbert Smith Freehills Kramer LLP